Form 4: Exagen CEO Aballi Reports Routine Stock Transactions

Exagen Inc. President and CEO John Aballi reported both a tax-related sale and an Employee Stock Purchase Plan acquisition of company common stock.

Summary

• John Aballi, President and CEO and Director of Exagen Inc. (XGN), reported transactions involving the company's common stock.
• On March 3, 2026, Aballi sold 15,698 shares of common stock at a price of $3.62 per share. This sale was mandated by Exagen Inc. to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units and was not a discretionary transaction.
• On the same date, Aballi acquired 2,535 shares of common stock at a price of $3.077 per share through the Employee Stock Purchase Plan (ESPP). This acquisition was voluntarily reported and exempt under Rule 16b-3(d) and Rule 16b-3(c).
• Following these transactions, Aballi directly beneficially owns 689,834 shares of common stock and indirectly owns 40,401 shares through his spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral filing. The mandated tax-related sale is a routine event, while the voluntary ESPP purchase shows continued insider investment, balancing the overall sentiment.

Positives

• The acquisition of 2,535 shares through the Employee Stock Purchase Plan (ESPP) indicates continued investment by the CEO in the company's equity.
• The ESPP acquisition was voluntary and exempt under Rule 16b-3(d) and Rule 16b-3(c), suggesting a standard, compliant employee benefit transaction.

Negatives

• The sale of 15,698 shares, although mandated for tax withholding, reduces the CEO's direct ownership in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions and typically do not provide broader industry context. These transactions reflect individual executive compensation and investment decisions rather than industry-wide trends.

Related Party Transactions

• Sale of 15,698 shares of common stock by CEO John Aballi to cover tax withholding obligations related to RSU vesting.
• Acquisition of 2,535 shares of common stock by CEO John Aballi through the Employee Stock Purchase Plan (ESPP).

Stakeholder Impact

• Shareholders: The transactions provide transparency regarding insider holdings and activity. The net effect on direct ownership is a slight decrease (15,698 sold vs. 2,535 acquired), but the overall direct and indirect holdings remain substantial.
• Employees: The ESPP acquisition highlights the availability and use of employee stock purchase programs, which can be a positive for employee morale and alignment with company performance.

Key Dates

Recommendation

The filing details routine insider transactions, including a tax-mandated sale and an ESPP purchase. These actions do not signal a significant change in the company's fundamentals or the CEO's long-term outlook, thus a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment thesis.

Keywords

Exagen Inc., XGN, John Aballi, Insider Trading, Form 4, Stock Sale, Stock Acquisition, ESPP, Restricted Stock Units, CEO, Director